| 1. |
- Gu, Yuanyu, et al.
(författare)
-
Magnetic hyperthermia with ϵ-Fe2O3nanoparticles
- 2020
-
Ingår i: RSC Advances. - : Royal Society of Chemistry. - 2046-2069. ; 10:48, s. 28786-28797
-
Tidskriftsartikel (refereegranskat)abstract
- Biocompatibility restrictions have limited the use of magnetic nanoparticles for magnetic hyperthermia therapy to iron oxides, namely magnetite (Fe3O4) and maghemite (γ-Fe2O3). However, there is yet another magnetic iron oxide phase that has not been considered so far, in spite of its unique magnetic properties: ϵ-Fe2O3. Indeed, whereas Fe3O4 and γ-Fe2O3 have a relatively low magnetic coercivity, ϵ-Fe2O3 exhibits a giant coercivity. In this report, the heating power of ϵ-Fe2O3 nanoparticles in comparison with γ-Fe2O3 nanoparticles of similar size (∼20 nm) was measured in a wide range of field frequencies and amplitudes, in uncoated and polymer-coated samples. It was found that ϵ-Fe2O3 nanoparticles primarily heat in the low-frequency regime (20-100 kHz) in media whose viscosity is similar to that of cell cytoplasm. In contrast, γ-Fe2O3 nanoparticles heat more effectively in the high frequency range (400-900 kHz). Cell culture experiments exhibited no toxicity in a wide range of nanoparticle concentrations and a high internalization rate. In conclusion, the performance of ϵ-Fe2O3 nanoparticles is slightly inferior to that of γ-Fe2O3 nanoparticles in human magnetic hyperthermia applications. However, these ϵ-Fe2O3 nanoparticles open the way for switchable magnetic heating owing to their distinct response to frequency.
|
|
| 2. |
- Rubia-Rodríguez, Irene, et al.
(författare)
-
Whither Magnetic Hyperthermia? : A Tentative Roadmap
- 2021
-
Ingår i: Materials. - : MDPI AG. - 1996-1944. ; 14:4
-
Tidskriftsartikel (refereegranskat)abstract
- The scientific community has made great efforts in advancing magnetic hyperthermia for the last two decades after going through a sizeable research lapse from its establishment. All the progress made in various topics ranging from nanoparticle synthesis to biocompatibilization and in vivo testing have been seeking to push the forefront towards some new clinical trials. As many, they did not go at the expected pace. Today, fruitful international cooperation and the wisdom gain after a careful analysis of the lessons learned from seminal clinical trials allow us to have a future with better guarantees for a more definitive takeoff of this genuine nanotherapy against cancer. Deliberately giving prominence to a number of critical aspects, this opinion review offers a blend of state-of-the-art hints and glimpses into the future of the therapy, considering the expected evolution of science and technology behind magnetic hyperthermia.
|
|
